Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody

NCT00360763 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

600

Enrollment

OTHER

Sponsor class

Conditions

Hypertension

Interventions

DRUG: candesartan cilexetil

Sponsor

Huazhong University of Science and Technology